<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="47865">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02483078</url>
  </required_header>
  <id_info>
    <org_study_id>PRO 140_CD 02</org_study_id>
    <nct_id>NCT02483078</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination w/ Optimized Background Therapy in Treatment-Experienced HIV Subjects</brief_title>
  <acronym>PRO 140</acronym>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CytoDyn, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amarex Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CytoDyn, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2b/3, multi-center, two part study, designed to evaluate the efficacy,
      safety, and tolerability of PRO 140 in conjunction with existing ART (failing regimen) for
      one week and Optimized Background Therapy (OBT) for 24 weeks respectively. Study population
      includes treatment-experienced HIV-infected patients with CCR5-tropic virus who demonstrates
      evidence of HIV-1 replication despite ongoing antiretroviral therapy with documented
      genotypic or phenotypic resistance to ART drugs within three drug classes (or within two or
      more drug classes with limited treatment options).The options may be limited as a result of
      drug antiviral class cross-resistance or documented treatment intolerance.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with ≥ 0.5 log10 reduction in HIV-1 RNA viral load from baseline at the end of the 1-week double-blind treatment period</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with ≥ 0.5 log10 reduction in HIV-1 RNA viral load from baseline at the end of the 1-week double-blind treatment period, stratified to each group:</measure>
    <time_frame>1 week</time_frame>
    <description>resistance to ART drugs within three drug classes
resistance to ART drugs within two or more drug class with limited treatment option.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline in HIV-1 RNA levels (log10 copies/mL) at the end of the 1-week double-blind treatment period for all patients and within each stratum</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving HIV-1 RNA &lt; 400 copies/mL at week 25 for all patients and within each stratum</measure>
    <time_frame>25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving HIV-1 RNA &lt; 50 copies/mL at week 25 for all patients and within each stratum</measure>
    <time_frame>25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline in HIV-1 RNA levels (log10 copies/mL) at week 25 for all patients and within each stratum</measure>
    <time_frame>25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline in CD4 cell count at the end of the 1-week double-blind treatment period for all patients and within each stratum</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline in CD4 cell count at week 25 for all patients and within each stratum</measure>
    <time_frame>25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with ≥ 1 log10 reduction in HIV-1 RNA viral load from baseline at the end of the 1-week double-blind treatment period for all patients and within each stratum</measure>
    <time_frame>1 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Tolerability of repeated subcutaneous administration of PRO 140 as assessed by study participants (using Visual Analogue Scale) and by investigator-evaluation of injection site reactions</measure>
    <time_frame>25 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of Grade 3 or 4 adverse events as defined by the DAIDS Adverse Event scale</measure>
    <time_frame>25 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of treatment-emergent serious adverse events</measure>
    <time_frame>25 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Emergence of Dual/Mixed (D/M)- and CXCR4-tropic virus in patients who had exclusive CCR5-tropic virus at study entry.</measure>
    <time_frame>25 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>PRO 140</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PRO140 350mg weekly SC Inj. + existing ART for one week. After one week, all subjects will enter the 24-week single-arm, open-label treatment period. During this period, all subjects will receive PRO 140 SC injection and Optimized Background Therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo weekly SC Inj. + existing ART for one week. After one week, all subjects will enter the 24-week single-arm, open-label treatment period. During this period, all subjects will receive PRO 140 SC injection and Optimized Background Therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO 140</intervention_name>
    <description>PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.</description>
    <arm_group_label>PRO 140</arm_group_label>
    <other_name>PRO140, CCR5 antagonist, Humanized monoclonal antibody to CCR5</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Optimized Background Regimen</intervention_name>
    <description>Optimized background therapy (OBT) is chosen on the basis of a subject's resistance test results and treatment history.</description>
    <arm_group_label>PRO 140</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females, age ≥ 18 years

          2. Exclusive CCR5-tropic virus at Screening Visit

          3. Have a history of at least 3 months on current antiretroviral regimen

          4. Treatment-experienced HIV-infected patients with documented genotypic or phenotypic
             resistance to at least one ART drug within three drug classes OR
             Treatment-experienced HIV-infected patients with documented genotypic or phenotypic
             resistance to at least one ART drug within two drug classes and have limited
             treatment options. The options may be limited as a result of drug antiretroviral
             class cross-resistance or documented treatment intolerance.

          5. Be willing to remain on treatment without any changes or additions to the OBT
             regimen, except for toxicity management or upon meeting criteria for treatment
             failure.

          6. Plasma HIV-1 RNA ≥ 400 copies/mL at Screening Visit and documented detectable viral
             load (HIV-1 RNA &gt;50 copies/ml) within the last 3 months prior to Screening Visit.

          7. Laboratory values at Screening of:

               -  Absolute neutrophil count (ANC) ≥ 750/mm3

               -  Hemoglobin (Hb) ≥ 10.5 gm/dL (male) or ≥ 9.5 gm/dL (female)

               -  Platelets ≥ 75,000 /mm3

               -  Serum alanine transaminase (SGPT/ALT) &lt; 5 x upper limit of normal (ULN)

               -  Serum aspartate transaminase (SGOT/AST) &lt; 5 x ULN

               -  Bilirubin (total) &lt; 2.5 x ULN unless Gilbert's disease is present or subject is
                  receiving atazanavir in the absence of other evidence of significant liver
                  disease

               -  Creatinine ≤ 1.5 x ULN

          8. Clinically normal resting 12-lead ECG at Screening Visit or, if abnormal, considered
             not clinically significant by the Principal Investigator

          9. Both male and female patients and their partners of childbearing potential must agree
             to use 2 medically accepted methods of contraception (e.g., barrier contraceptives
             [male condom, female condom, or diaphragm with a spermicidal gel], hormonal
             contraceptives [implants, injectables, combination oral contraceptives, transdermal
             patches, or contraceptive rings], and intrauterine devices) during the course of the
             study (excluding women who are not of childbearing potential and men who have been
             sterilized). Females of childbearing potential must have a negative serum pregnancy
             test at Screening visit and negative urine pregnancy test prior to receiving the
             first dose of study drug.

         10. Willing and able to participate in all aspects of the study, including use of SC
             medication, completion of subjective evaluations, attendance at scheduled clinic
             visits, and compliance with all protocol requirements as evidenced by providing
             written informed consent.

        Note: Subjects diagnosed with either substance dependence or substance abuse or any
        history of a concomitant condition (e.g., medical, psychologic, or psychiatric) may be
        enrolled if in the opinion of site investigator these circumstances would not interfere
        with the subject's successful completion of the study requirements.

        Exclusion Criteria:

          1. Documented CXCR4-tropic virus or Dual/Mixed tropic (R5X4) virus

          2. Patients with no viable treatment options (≤ 1 fully active approved drug)

          3. Any active infection or malignancy requiring acute therapy (with the exception of
             local cutaneous Kaposi's sarcoma) Note: Subjects infected by the hepatitis B virus or
             early stage hepatitis C virus will be eligible for the study.

          4. Laboratory test values of ≥ grade 3 DAIDS laboratory abnormality with the exception
             of the absolute CD4+ count criterion of &lt; 200/mm3

          5. Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant
             during the study

          6. Unexplained fever or clinically significant illness within 1 week prior to the first
             study dose

          7. Any vaccination within 2 weeks prior to the first study dose.

          8. Subjects weighing &lt; 35kg

          9. History of anaphylaxis

         10. History of Bleeding Disorder or patients on anti-coagulant therapy

         11. Prior use of maraviroc or any other CCR5 co-receptor antagonist

         12. Participation in an experimental drug trial(s) within 30 days of the Screening Visit
             or during the study

         13. Any known allergy or antibodies to the study drug or excipients

         14. Treatment with any of the following:

               -  Radiation or cytotoxic chemotherapy with 30 days prior to the Screening Visit or
                  during the study

               -  Immunosuppressants within 60 days prior to the Screening Visit or during the
                  study

               -  Immunomodulating agents (e.g., interleukins, interferons), hydroxyurea, or
                  foscarnet within 60 days prior to the Screening Visit or during the study

               -  Oral or parenteral corticosteroids within 30 days prior to the Screening Visit
                  or during the study. Subjects on chronic steroid therapy &gt; 5 mg/day will be
                  excluded with the following exception:

                    -  Subjects on inhaled, nasal, or topical steroids will not be excluded.

         15. Any other clinical condition that, in the Investigator's judgment, would potentially
             compromise study compliance or the ability to evaluate safety/efficacy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edwin DeJesus, MD, FACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>1707 North Mills Avenue Orlando, Florida 32803</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kush Dhody, MBBS, MS, CCRA</last_name>
    <phone>(301)956-2536</phone>
    <email>kushd@amarexcro.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lalla-Reddy Medical Corporation</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>714-968-6789</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Long Beach Education and Research Consultants</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>562-624-4943</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>W. King Health Care Group</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>323-617-5409</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Global Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>818-601-8475</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Palmtree Clinical Research Inc.</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>760-778-7799</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Quest Clinical Research</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Northern CA</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>415-833-2427</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>203-785-3557</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Circle CARE Center</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>203-852-9525</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Whitman-Walker Health</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Providence Hospital DC</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>443-859-2755</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tampa Bay Medical Research Inc</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>727-724-3316</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Therafirst Medical Center</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Midway Immunology and Research Center</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>772-595-9830</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AIDS Healthcare Foundation- South Beach</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33139</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>305-538-1400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>BioMed Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>305-267-4123</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SouthCoast Research Center, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>786-343-6937</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Elite Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>305-620-7002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>1707 North Mills Avenue</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janiza Veloz, CCRC</last_name>
      <phone>407-647-3960</phone>
      <email>jveloz@oicorlando.com</email>
    </contact>
    <investigator>
      <last_name>Edwin DeJesus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>407-647-3960</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Triple O Research Institute, P.A.</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>561-855-7871</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Howard Brown Health Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>773-572-5116</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Via Christi Research</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>316-268-6958</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>E Study Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>702-410-2970</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ACRIA</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>212-924-3934</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chelsea Village Medical</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>212-929-2629</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>135-464-5729</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases Research Center, University of Cincinnatti</name>
      <address>
        <city>Cincinnatti</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>513-584-6383</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Texas Clinical Research LLC</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>512-480-9660</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Hope Foundation, Inc</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>713-844-8035</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Texas Infectious Disease Consultants, PA</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>214-276-5654</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Therapeutic Concepts, PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>713-526-9821</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Access Network</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>713-526-7732</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Alliance for Research &amp; Education - Infectious Diseases, LLC - CARE-ID</name>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <zip>22003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>703-560-4821</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>509-343-3710</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ponce Medical School Foundation INC - CAIMED Center</name>
      <address>
        <city>Ponce</city>
        <zip>00716-2347</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>787-840-2505</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Puerto Rico</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>787-723-5945</phone>
    </contact>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 17, 2016</lastchanged_date>
  <firstreceived_date>June 24, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>HIV Antibodies</mesh_term>
    <mesh_term>PRO-140 monoclonal antibody</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
